Posts

WOW!: RevMed and Tango’s pancreatic cancer combo achieves 92% response

on

Revolution Medicines Confident in RAS Leadership as Rivals Square Up: Recent News Summary (June 2026)

on

ASCO26: With daraxonrasib in the spotlight, Immuneering makes case for its drug in 1L pancreatic cancer

on

ASCO26: Revolution presents Phase III data that rewrites odds in pancreatic cancer

on

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Erasca and Revolution Medicines Clash Over RAS Patent Infringement for ERAS-0015

on

Revolution Medicines Buyout Valuation Post-Phase 3: Talks Collapse at $30B

on

Pivotal Pancreatic Cancer Data Fuels Revolution Medicines' Upsized $2B Offering

on

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up

on

Revolution Medicines' Daraxonrasib Doubles Survival in Phase 3 Pancreatic Cancer Trial

on

Revolution Medicines Advances Daraxonrasib in Phase 3 Pancreatic Cancer Trial After Hitting Key Goals

on

Revolution Medicines Rejects Merck's Acquisition Bid, Stands Firm on Valuation Amid Ongoing Interest

on

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

on

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

on

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

on

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

on

Deal Roundup: Novartis Options Sironax's Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

on

Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

on

Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development

on